Vaxcyte Inc. (PCVX)
37.81
-31.65 (-45.57%)
At close: Mar 31, 2025, 3:59 PM
37.50
-0.82%
After-hours: Mar 31, 2025, 06:47 PM EDT
Vaxcyte Income Statement
| Year | FY24 | FY23 | FY22 | FY21 | FY20 | FY19 | FY18 | FY17 |
| Revenue | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost of Revenue | n/a | 75M | 9.2M | 1.8M | 1.41M | 1.23M | 1.04M | n/a |
| Gross Profit | n/a | -75M | -9.2M | -1.8M | -1.41M | -1.23M | -1.04M | n/a |
| Operating Income | -569.55M | -468.04M | -232.26M | -103.67M | -89.58M | -54.15M | -35.53M | -17.83M |
| Interest Income | 109.99M | 62.91M | 8.36M | 344K | 244K | 632K | 903K | 164K |
| Pretax Income | -463.93M | -402.27M | -223.49M | -100.08M | -89.22M | -50.27M | -29.48M | -17.24M |
| Net Income | -463.93M | -402.27M | -239.64M | -100.08M | -87.82M | -53.5M | -29.48M | -17.24M |
| Selling & General & Admin | 92.9M | 60.7M | 39.81M | 25.26M | 16.02M | 8.55M | 5.39M | 5.05M |
| Research & Development | 476.64M | 332.34M | 169.45M | 78.41M | 73.56M | 45.61M | 30.14M | 12.79M |
| Other Expenses | n/a | n/a | -1.93M | -1.58M | -2.48M | -237K | 5.18M | n/a |
| Operating Expenses | 569.55M | 468.04M | 207.33M | 102.08M | 87.1M | 53.92M | 35.53M | 17.4M |
| Interest Expense | n/a | n/a | 2K | 7K | 7K | 40K | 75K | n/a |
| Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Cost & Expenses | n/a | 468.04M | 207.33M | 102.08M | 87.1M | 53.92M | 35.53M | 17.4M |
| Income Tax | n/a | n/a | 16.16M | 7K | -1.4M | 3.23M | 6.12M | n/a |
| Shares Outstanding (Basic) | 122M | 97.16M | 64.88M | 51.92M | 29.55M | 3.79M | 3.63M | 3.56M |
| Shares Outstanding (Diluted) | 122M | 97.16M | 64.88M | 51.92M | 29.55M | 3.8M | 3.63M | 3.57M |
| EPS (Basic) | -3.8 | -4.14 | -3.69 | -1.93 | -2.97 | -14.1 | -8.12 | -4.84 |
| EPS (Diluted) | -3.8 | -4.14 | -3.69 | -1.93 | -2.97 | -14.1 | -8.12 | -4.83 |
| EBITDA | -569.55M | -464.88M | -214.29M | -98.28M | -87.81M | -49M | -28.37M | -17.21M |
| Depreciation & Amortization | n/a | 3.16M | 9.2M | 1.8M | 1.41M | 1.23M | 1.04M | 625K |